Jason EkertPhD, MBA
Dr Ekert leads an integrated enterprise strategy for sustained, portfolio driven growth in R&D application of complex human-relevant and translatable complex in vitro models. Dr. Ekert's group drives the coordination and prioritization of development and integrated use of complex in vitro technologies for efficacy, safety, and bio metabolism studies. Dr. Ekert received his Ph.D. in Medical Science from Adelaide University in Australia. He performed post-doctoral training at the University of California, Davis and Coriell Institute for Medical Research.
Before coming to GSK Dr Ekert worked for 11 years at Janssen BioThereapeutics in early biotherapeutic drug discovery in target discovery, drug validation and mechanism of action studies applying 3D cell cultures, iPSCs and primary cells in complex cell-based assays across multiple therapeutic areas. His current focus at GSK is to improve the predictive validity of early preclinical models leading to better-characterized molecules, decreased R&D cycle time and a reduction in attrition.